Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
  • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
  • C12Y603/02002—Glutamate-cysteine ligase (6.3.2.2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/53—Ligases (6)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/52—Genes encoding for enzymes or proenzymes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/93—Ligases (6)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2740/00—Reverse transcribing RNA viruses
  • C12N2740/00011—Details
  • C12N2740/10011—Retroviridae
  • C12N2740/16011—Human Immunodeficiency Virus, HIV
  • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
  • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

• the disclosure relates to compositions and methods for providing chemoprotective effects to target cells.
• the methods comprise providing a heterologous glutamate-cysteine ligase (GCL) modifier subunit (GCLM), GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• GCL glutamate-cysteine ligase
• GCLC GCL catalytic subunit
• GCL as a dimer or a full enzyme
• the heterologous gene/protein is GCLM.
• methods for providing or improving chemoprotection in a patient in need thereof comprise administering to the patient a heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• GCL glutamate-cysteine ligase
• GCLC GCL catalytic subunit
• GCL as a dimer or a full enzyme
• the heterologous gene/protein is GCLM.
• Additional embodiments provide transgene expression of glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function and allows for post-transplant in vivo selection.
• GCL glutamate-cysteine ligase
• the cells are stem cells or immune cells.
• the stem cell are fetal stem cells, cord blood derived stem cells, hematopoietic stem cells (HSCs), pluripotent stem cells (PSCs), induced PSCs (iPSCs), embryonic stem cells (ESCs) or cells derived therefrom, such as CD34+ cells, CD90+ cells, CD45+ cells, CD 17+ cells, CD45RA- cells, or any combination thereof.
• HSCs hematopoietic stem cells
• PSCs pluripotent stem cells
• iPSCs induced PSCs
• ESCs embryonic stem cells
• the immune cells are T cells.
• the modified cells are autologous to the patient, allogeneic to the patient, or a combination thereof.
• the method further comprises contacting unmodified cells with an expression vector encoding for the expression of glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• GCL glutamate-cysteine ligase
• the expression vector encodes for GCLM.
• the expression vector is a viral vector or a non- viral vector.
• the viral vector is a lentiviral or adenoviral vector.
• the expression vector is a retrovirus, a transposon, an episomal expression vector, modified RNA, a plasmid, or any combination thereof.
• the patient is undergoing gene therapy, cell therapy, or CAR-T therapy.
• the chemoprotection provided is to busulfan and/or naphthalene.
• FIG. 1 illustrates the glutathione synthesis pathway and the utilization of busulfan.
• FIG. 2A illustrates a lentiviral engineered construct overexpressing human GCLM and GFP.
• FIG. 2B illustrates embodiments provided for herein.
• FIG. 3A and FIG. 3B illustrate unchanged proliferation rate and increased GSH in GCLM- transduced cells.
• GSH level changes between untransduced and transduced Jurkat, CEM and TF- la cells were 2.1, 1.7, and 1.9-fold, respectively.
• Untransduced CEM cells were found to be most sensitive to busulfan exposure. There was no effect on cell viability and proliferation due to the overexpression of GCLM.
• FIG. 4 illustrates GCLM-transduced CEM cells maintained high level of GSH.
• FIG. 4 shows that there was a 1.7 fold increase in GSH level in GCLM-transduced cells and that the GSH level remained at least 3.5-fold higher in transduced cells at different dose and time at 24-hr post busulfan exposure.
• FIG. 5 illustrates GCLM-transduced cells being protected at low dosage of busulfan.
• GCLM transduced-CEM cells displayed at least 3.5 fold proliferate rates/protection against lower doses of busulfan exposure.
• FIG. 6 illustrates GCLM-transduced cells being protected at higher dosage of busulfan.
• busulfan the untransudced cells were all dead by 96 hours while the viable transduced cells had expanded 5- and 3- folds with 10 and 20 mg/ml of busulfan, respectively.
• FIG. 7 illustrates proliferation of GCLM-transduced CEM cells after 1 or 2 hours exposure of busulfan.
• GCLM-transduced CEM cells were similarly protected from 10 or 20 mg/ml and 1- hr or 2-hr busulfan exposure and reached 100% from 20% initial transduced cell population b 96 hours.
• administering refers to introducing an agent (e.g., a cell) into a subject.
• an effective amount is administered, which amount can be determined by the treating physician or the like.
• Any route of administration such as topical, subcutaneous, peritoneal, intravenous, intraarterial, inhalation, vaginal, rectal, nasal, oral, buccal, introduction into the cerebrospinal fluid, or instillation into body compartments can be used.
• administering and “administration of,” when used in connection with a composition (and grammatical equivalents) refer both to direct administration, which may be administration to a patient by a medical professional or by self-administration by the patient, and/or to indirect administration, which may be the act of prescribing a drug.
• direct administration which may be administration to a patient by a medical professional or by self-administration by the patient
• indirect administration which may be the act of prescribing a drug.
• a physician who instructs a patient to self- administer an agent (e.g., a cell) and/or provides a patient with a prescription for a drug is administering the agent to the patient.
• Periodic administration or “periodically administering” refers to multiple treatments that occur on a daily, weekly, or a monthly basis. Periodic administration may also refer to administration of an agent one, two, three or more time(s) per day.
• the terms “comprising” (and any form of comprising, such as “comprise”, “comprises”, and “comprised”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), or “containing” (and any form of containing, such as “contains” and “contain”), are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. Any step or composition that uses the transitional phrase of “comprise” or “comprising” can also be said to describe the same with the transitional phase of “consisting of’ or “consists.”
• an “effective amount” is an amount of an agent or compound (e.g., cell or population of cells) sufficient to effect beneficial or desired results.
• An effective amount can be in one or more administrations, applications or doses. Determination of these parameters is well within the skill of the art. These considerations, as well as effective formulations and administration procedures are well known in the art and are described in standard textbooks.
• heterologous when referencing a nucleic acid molecule, protein, vector, or expression cassette refers to a nucleic acid molecule, protein, vector, or expression cassette that is expressed in a cell through the manipulation of a user and is not naturally occurring.
• a heterologous gene refers to a gene that is expressed by a vector or other vehicle that is put in the cell or to a gene that is in the genome that has been modified through a gene editing methods, such as CRISPR, or other recombination techniques to replace the gene in a cell.
• CRISPR CRISPR
• heterologous does not refer to a naturally occurring gene in the genome of a cell that has not been modified.
• Heterologous can also be referred to as “exogenous.” Therefore, in some embodiments, a cell can express the same protein both heterologously and from its own genome (endogenous).
• isolated refers to molecules separated from other DNAs or RNAs, respectively that are present in the natural source of the macromolecule.
• isolated refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
• an isolated nucleic acid is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state.
• An “isolated cell,” for example, an isolated bone marrow cell is a cell that is substantially free of other cellular material, tissue, medium of the environment in which it is naturally found.
• myelo ablative means a treatment that causes long lasting (usually irreversible) pancytopenia, kills cells in the bone marrow within 1 to 3 weeks from administration, and does not allow autologous hematologic recovery.
• myeloablative doses of cyclophosphamide include, without limitation, 2.5 mg/kg/day CTX or greater for a period of time that results in cumulative toxicity (McKinley et al., Clin J Am Soc Nephrol. 2009, 4:1754-1760).
• non-myeloablative means a treatment that causes no, minimal, or reversible cytopenia with little toxicity.
• Non-myeloablative regimens are immuno-ablation.
• Examples of non-myeloablative doses include, without limitation, approximately 1.3 mg/kg/day for a period of time that does not result in cumulative toxicity or 1.0 to 1.5 mg/kg/day for 2 to 4 months (McKinley et al., Clin J Am Soc Nephrol. 2009, 4:1754-1760).
• Other non-myeloablative doses are described throughout and are included within the definition of non-myeloablative doses.
• An agent or dose of an agent that results in “cumulative toxicity” refers to a dose that over time will lead to toxicity in the patient.
• cyclophosphamide that is administered to a human at a dose of 2.5 mg/kg/day for a period of weeks will lead to cumulative toxicity.
• Other examples of a non- myeloablative doses can be found, for example, in U.S. Publication No. 2019/0269734, which is hereby incorporated by reference in its entirety.
• a “subject,” “individual” or “patient” is used interchangeably herein and refers to a vertebrate, for example a primate, a mammal or preferably a human. Mammals include, but are not limited to equines, canines, bovines, ovines, murines, rats, simians, and humans.
• sequence identity refers to the percentage of amino acid residues (or nucleotide residues) in a candidate sequence that are identical to the amino acid residues in the specific protein or amino acid sequence (or nucleotide residues in the specific DNA or RNA sequence), after aligning the sequences and introducing gaps, if necessary, to achieve a maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment can be achieved by any method known to one of skill in the art, for example, by using publicly available programs such as BLAST and EMBOSS.
• variant is a nucleic acid or protein that differs from a reference nucleic acid or protein, but retains essential properties (i.e., biological activity).
• a typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions, and/or truncations in the polypeptide encoded by the reference sequence.
• vector is used herein to refer to a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule.
• the transferred nucleic acid is generally linked to, for example, the vector nucleic acid molecule.
• a vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into cellular DNA.
• Vectors include, for example, plasmids (e.g., DNA plasmids or RNA plasmids), transposons, cosmids, bacterial or yeast artificial chromosomes and viral vectors.
• Useful viral vectors include, for example, adenoviruses, retroviruses, such as, but not limited to, replication defective retroviruses, and lentiviruses.
• phrases “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• GCLM when referring to the protein form, refers to a protein comprising the sequence of SEQ ID NO: 1 or a variant thereof.
• the GCLM protein is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical or substantially identical to SEQ ID NO: 1.
• the sequence of the protein is also provided for in Genbank Accession No. NM_002061.3 or NP_002052.1, each of which is hereby incorporated by reference in its entirety.
• Genbank Accession No. NM_002061.3 provides for one example of a nucleic acid molecule that can encode for SEQ ID NO: 1.
• GCLM when referring to a nucleotide form, refers to a nucleic acid molecule that encodes for GCLM.
• the nucleic acid molecule comprising the sequence of SEQ ID NO: 2 or a variant thereof, wherein such variant can be substantially identical to SEQ ID NO: 2.
• SEQ ID NO: 2 is a non-limiting example and other nucleotide sequences can be used to encode the GCLM protein or a protein that is identical or substantially identical to the protein.
• SEQ ID NO: 2 is as follows:
• the nucleotide sequence comprises the coding region of SEQ ID NO: 2, which is nucleotides 436 to 1260 of SEQ ID NO: 2.
• the nucleic acid molecule only comprises the coding region of SEQ ID NO: 2 or a sequence that encodes the GCLM protein, or a variant thereof.
• the variant, as described herein, can have substitutions or mutations. In some embodiments, the substitutions are conservative substitutions.
• the GCLM protein variant is substantially identical to SEQ ID NO: 1.
• Sequence identity, percentage identity, and related terms refer to the relatedness of two sequences, e.g., two nucleic acid sequences or two amino acid or polypeptide sequences.
• amino acid sequence the term “substantially identical” is used herein to refer to a first amino acid that contains a sufficient or minimum number of amino acid residues that are i) identical to, or ii) conservative substitutions of aligned amino acid residues in a second amino acid sequence such that the first and second amino acid sequences can have a common structural domain and/or common functional activity.
• amino acid sequences that contain a common structural domain having at least about 85%, 90%.
• nucleotide sequence 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein, such as SEQ ID NO: 1.
• a reference sequence e.g., a sequence provided herein, such as SEQ ID NO: 1.
• substantially identical is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity.
• nucleotide sequences having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence, e.g., a sequence provided herein.
• the percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
• the comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm.
• the percent identity between two amino acid sequences is determined using the Needleman and Wunsch ((1970) J. Mol. Biol.
• the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6.
• a particularly preferred set of parameters are a Blossum 62 scoring matrix with a gap penalty of 12, a gap extend penalty of 4, and a frameshift gap penalty of 5.
• the percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller ((1989) CABIOS, 4:11-17) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
• amino acid is intended to embrace all molecules, whether natural or synthetic, which include both an amino functionality and an acid functionality and capable of being included in a polymer of naturally-occurring amino acids.
• exemplary amino acids include naturally-occurring amino acids; analogs, derivatives and congeners thereof; amino acid analogs having variant side chains; and all stereoisomers of any of any of the foregoing.
• amino acid includes both the D- or L-optical isomers and pep tido mimetic s.
• a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain.
• Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
• Cells for use in the disclosed chemoprotective methods may be any suitable cell known to one of skill in the art.
• the cells can be stem cells or immune cells.
• stem cells include a cord blood cell, fetal stem cell, embryonic stem cell (ESC), hematopoietic stem cell (HSC), hematopoietic progenitors cell, pluripotent stem cell (PSC), induced PSC (iPSC), or a cell derived therefrom.
• the immune cell is a T cell.
• the cells are CD34+ and/or CD4+.
• the cells are mesenchymal stem cells, stromal stem cells, cord blood derived hematopoietic stem/progenitor cells, cord tissue derived stem/progenitor cells, iPSCs, HESCs, fetal tissue derived stem cells, CD4+ cells, and the like.
• the stem cells are CD34+.
• compositions and methods described herein can be utilized in bone marrow transplant situations such as those described in W02020/018413.
• provided herein are methods for performing a bone marrow transplant in a patient in need thereof. Also are provided for methods for replacing a subject's bone marrow cells with a population of cells expressing a heterologous nucleic acid molecule expression cassette or a plurality of heterologous expression cassettes or with a cell that has had its genome edited and differs from the subject's genome.
• the heterologous protein expressed is GCLM or a variant thereof.
• these methods comprise administering to the patient one or more chemotherapeutic-resistant modified cells and administration of at least one dose of a chemotherapeutic agent.
• the dose is a non-myeloablative dose of a chemotherapeutic agent. In certain embodiments, the dose is a myeloablative dose of a chemotherapeutic agent. In some embodiments, the amount of the cells is a therapeutically effective amount. In some embodiments, the chemotherapy that is administered is busulfan.
• the chemotherapeutic is one or more of: actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, busulfan, capecitabine, carboplatin, carmustine (BCNU), cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, lomustine (CCNU), mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, nimustin (ACNU) oxaliplatin, paclitaxel, pemetrexed, warmth
• chemotherapeutic-resistant modified cells for use in the disclosed methods may be any suitable cell known to one of skill in the art.
• the cells can be stem cells or immune cells.
• stem cells include a cord blood cell, fetal stem cell, embryonic stem cell (ESC), hematopoietic stem cell (HSC), hematopoietic progenitors cell, pluripotent stem cell (PSC), induced PSC (iPSC), or a cell derived therefrom.
• the immune cell is a T cell.
• the cells are CD34+ and/or CD4+.
• the cells are mesenchymal stem cells, stromal stem cells, cord blood derived hematopoietic stem/progenitor cells, cord tissue derived stem/progenitor cells, iPSCs, HESCs, fetal tissue derived stem cells, CD4+ cells, and the like.
• the stem cells are CD34+.
• Chemotherapeutic -resistant modified cells for use in the present methods may be cells from a patient (i.e., autologous cells), cells from a donor (i.e., allogeneic cells), or any combination thereof that have been modified to confer chemotherapeutic resistance through the expression of a heterologous protein, such as GCLM or a variant thereof.
• the methods provided herein further comprise isolating and/or purifying cells from a patient or a donor.
• the methods further comprise modifying the cells to be chemotherapeutic resistant.
• methods for performing a bone marrow transplant in a patient in need thereof comprising isolating and/or purifying one or more cells from a patient or subject, modifying the one or more cells to be chemotherapeutic resistant as described herein, administering to the patient an effective amount of the one or more chemotherapeutic -resistant modified cells, and administering at least one dose of a chemotherapeutic agent.
• Cells can be isolated by any method known to one of skill in the art, for example, based on expression/lack of expression of certain markers, rates of proliferation, and differentiation potential.
• the cells are isolated based on the presence of a particular marker or combination of markers including, for example, CD34, CD4, Sca-1 CD38, CD123, CD90, CD45, CD133, antigen presenting cell markers (CD8, CD8alpha, CDllb, CDllc, CD103, CD205, CD24, CD115, CD117, CD135, CDllc low , CD45RA, CD123, ILT-7, MHC class II, MHC Class II low , TLR7, and/or TRL9).
• a particular marker or combination of markers including, for example, CD34, CD4, Sca-1 CD38, CD123, CD90, CD45, CD133, antigen presenting cell markers (CD8, CD8alpha, CDllb, CDllc, CD103, CD205, CD24, CD115, CD117, CD135, CDllc low , CD
• the cells are isolated based on the absence of a particular marker, for example, CD3, CD14, CD19, CD56, and/or CD66b. In other embodiments, negative selection is performed for markers of, for example, T cells, B cells, granulocytic, and/or myelomonocytic cells. In some embodiments, cells are isolated based on the presence of Thy-1 alone or in combination with any other marker. In some embodiments, HSCs are isolated based on Lin l hyl+Sca_l+ expression profile. In some embodiments, mouse HSCs can be isolated by the expression profile CD34 , Seal , c-kit + . In some embodiments human HSCs can be isolated based on CD34 expression.
• the methods provided herein comprise administering one or more doses of a chemotherapeutic agent to the patient.
• the dose is a non-myeloablative dose of a chemotherapeutic agent.
• the dose is myeloablative.
• the chemotherapeutic agent can be any suitable chemotherapeutic agent known to one of skill in the art.
• Non-limiting examples of chemotherapeutic agents include actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, busulfan, capecitabine, carboplatin, carmustine (BCNU), cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, lomustine (CCNU), mechlorethamine, melphalan, mercaptopurine, methotrexate, mitoxantrone, nimustin (ACNU) oxaliplatin, paclitaxel, pemetrexed, temezolamide,
• the methods provided herein comprise administering to the subject an effective amount of the chemotherapeutic-resistance modified cells and a non-myeloablative dose of a chemotherapeutic agent.
• the modified cells and chemotherapeutic agent can be administered by any appropriate route, which will be apparent to the skilled person depending on the disease or condition to be treated. Typical routes of administration include intravenous, intra arterial, intramuscular, subcutaneous, intracranial, intranasal, intradermal, oral or intraperitoneal.
• about 1 x 10 s to about l x 10 11 cells per m 2 of body surface area of the subject are administered to the subject.
• the cells can be administered to an individual by absolute numbers of cells, e.g., said individual can be administered from about 1000 cells/injection to up to about 10 billion cells/injection, such as at about, at least about, or at most about, 1 x 10 s , 1 x 10 7 , 5 x 10 7 , 1 x 10 6 , 5 x 10 6 , 1 x 10 5 , 5 x 10 5 , 1 x 10 4 , 5 x 10 4 , 1 x 10 3 , 5 x 10 3 (and so forth) cells per injection, or any ranges between any two of the numbers, end points inclusive.
• about 5 x 10 6 /kg to about 10 x 10 6 /kg of cells are used for a HSC transplant.
• the subject can be administered from about 1000 cells/injection/m 2 to up to about 10 billion cells/injection/m 2 , such as at about, at least about, or at most about, 1 x 10 8 /m 2 , 1 x 10 7 /m 2 , 5 x 10 7 /m 2 , lx 10 6 /m 2 , 5 x 10 6 /m 2 , lx 10 5 /m 2 , 5 x 10 5 /m 2 , 1 x 10 4 /m 2 , 5 x 10 4 /m 2 , 1 x 10 3 /m 2 , 5 x 10 3 /m 2 (and so forth) cells per injection, or any ranges between any two of the numbers, end points inclusive.
• the cells can be administered to such individual by relative numbers of cells, e.g., said individual can be administered about 1000 cells to up to about 10 billion cells per kilogram of the individual, such as at about, at least about, or at most about 1 x 10 s , 5 x 10 7 , 1 x 10 7 , 5 x 10 6 , 1 x 10 6 , 5 x 10 5 , 1 x 10 5 , 5 x 10 4 , 1 x 10 4 , 5 x 10 3 , 1 x 10 3 , (and so forth) cells per kilogram of the individual, or any ranges between any two of the numbers, end points inclusive.
• At least one non-myeloablative dose of a chemotherapeutic agent is administered to the patient.
• the administration of the chemotherapeutic agent can occur concurrently or sequentially with the administration of the modified cells.
• at least one non-myeloablative dose of the chemotherapeutic agent is administered after administration of the modified cells.
• a preconditioning step (also referred to herein as “pretreatment step”) is performed prior to administration of the cells wherein the patient is administered at least one dose of a chemotherapeutic agent, for example, fludarabine or cyclophosphamide, prior to administration of the modified cells.
• the preconditioning step is a non-myeloablative chemotherapeutic preconditioning step.
• a preconditioning step is not performed prior to administration of the cells. It is contemplated that cells of the present disclosure will still be able to efficiently engraft into the patient’s bone marrow even without the preconditioning step (e.g., fludarabine) prior to administration of the cells.
• the at least one non-myeloablative dose of a chemotherapeutic agent for a human subject or patient is a non-myeloablative dose of busulfan.
• the non-myeloablative dose of cyclophosphamide is from about 0.1 mg/kg/day to about 8 mg/kg/day, about 0.1 mg/kg/day to about 7 mg/kg/day, about 0.1 mg/kg/day to about 6 mg/kg/day, about 0.1 mg/kg/day to about 5 mg/kg/day, about 0.1 mg/kg/day to about 4 mg/kg/day, about 0.1 mg/kg/day to about 3 mg/kg/day, about 0.1 mg/kg/day to about 2 mg/kg/day, about 0.1 mg/kg/day to about 1 mg/kg/day, about 0.5 mg/kg/day to about 8 mg/kg/day, about 0.5 mg/kg/day to about 7 mg/kg/day, about 0.5 mg
• the non-myeloablative dose is about 0.1 mg/kg, about 0.5 mg/kg, about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, or about 8 mg/kg. In some embodiments, the non-myeloablative dose is less than 8 mg/kg.
• the dose can be administered on a daily basis.
• a myeloablative dose is administered.
• the myeloablative dose of busulfan is about 8 to about 12mg/kg, which can be in a day.
• the non-myeloablative dose of the chemotherapeutic agent is administered every day for at least about 1 day, at least about 2 days, at least about 3 days, at least about 4 days, at least about 5 days, at least about 6 days, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 1 year, or longer.
• the non-myeloablative dose is provided for a period of time that does not result in cumulative toxicity.
• the period of time that does not result in cumulative toxicity is a period of times less than about 1 year, less than about 6 months, less than about 3 months, less than about 2 months, less than about 1 month, less than about 3 weeks, less than about 2 weeks, less than about 1 week, less than about 6 days, less than about 5 days, less than about 4 days, less than about 3 days, or less than about 2 days.
• the period of time can be for about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about a month, about 2 months, about 3 months, about 6 months, about a year or more. In some embodiments, the period of time is about 3 days, about 7 days, about 10 days, and about 14 days.
• greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells. In some embodiments, greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about a year. In some embodiments, greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 6 months. In some embodiments, greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 5 months.
• greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 4 months. In some embodiments, greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 3 months. In some embodiments, greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 2 months. In some embodiments, greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 1 month.
• greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 2 weeks. In some embodiments, greater than about 60%, about 70%, about 80%, about 90%, about 95%, or 100% of the patient’s bone marrow is replaced with the modified cells within about 1 week.
• the patient is not myeloablated and/or immunocompromised during the method.
• the patient does not experience clinically relevant anemia, neutropenia, thrombocytopenia, pancytopenia, low platelets, low white blood cells, low red cells, or any combination thereof or related symptom(s).
• the subject or subject group may exhibit one or more of the following outcomes:
• an increase in white blood cells of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least 60%, at least 65%, at least 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (actual % change or median % change) as compared to a control;
• an increase in neutrophils of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least 60%, at least 65%, at least 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (actual % change or median % change) compared to a control;
• an increase in lymphocytes of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least 60%, at least 65%, at least 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (actual % change or median % change) compared to a control;
• an increase in eosinophils of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least 60%, at least 65%, at least 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (actual % change or median % change) compared to a control;
• an increase in monocytes of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least 60%, at least 65%, at least 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (actual % change or median % change) compared to a control;
• an increase in basophils of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least 60%, at least 65%, at least 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (actual % change or median % change) compared to a control;
• an increase in red blood cells of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least 60%, at least 65%, at least 70%, at least about 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% (actual % change or median % change) compared to a control;
• (x) no relapse for a period of at least about 6 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 15 years, about 20 years, about 25 years, about 30 years, about 35 years, about 40 years, about 45 years, about 50 years, about 55 years, about 60 years, or longer;
• (xii) an increase in survival of a patient of at least about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, about 15 years, about 20 years, about 25 years, about 30 years, about 35 years, about 40 years, about 45 years, about 50 years, about 55 years, about 60 years, or longer as compared to a control.
• the chemotherapeutic-resistant modified cells may comprise one or more additional modifications unrelated to chemotherapeutic resistance.
• the cells may be further modified to express additional HIV/disease-specific modifications.
• the bone marrow transplant methods provided herein further comprise incorporating one or more additional modifications, including one or more HIV/disease- specific modifications.
• methods for performing a bone marrow transplant in a patient in need thereof comprising isolating and/or purifying one or more cells from a patient or subject, modifying the one or more cells to be chemotherapeutic resistant as described herein, incorporating one or more additional modifications into the one or more cells, administering to the patient an effective amount of the one or more chemotherapeutic-resistant modified cells, and administering at least one dose of a chemotherapeutic agent.
• the dose is a non-myeloablative dose of a chemotherapeutic agent.
• the modified cells are further modified to be HIV resistant.
• the modified cell can be further modified to express at least one mutant HIV co receptor that confers resistant to HIV infection, a mutation or plurality of mutations of at least one HIV co-receptor, expression of at least one HIV fusion inhibitor, or any combination thereof.
• the cells are modified to express a molecule that inhibits or reduces the expression of a HIV co-receptor.
• the molecule is an antisense molecule.
• the cells are modified to express shCCR5, shCXCR4, a GP-41 fusion inhibitor, C46 fusion inhibitor, a C34 fusion inhibitor, any other C-peptide fusion inhibitor, or any combination thereof.
• the CCR5 mutation is the CCR5-delta 32 mutation. In some embodiments, both copies of the CCR5 gene in the cells are replaced with the CCR5-delta 32 mutation. In some embodiments, one copy of the CCR5 gene is replaced with the CCR5-delta 32 mutation.
• the present disclosure provides cells that are modified to have chemotherapeutic resistance, for example cyclophosphamide resistance, and HIV resistance.
• cells may be modified to have cyclophosphamide resistance and HIV resistance.
• the HIV-resistance may be conferred by reduced expression of at least one HIV co-receptor, a mutation or plurality of mutations of at least one HIV co-receptor, expression of at least one HIV fusion inhibitor, or any combination thereof.
• the HIV-resistance may be conferred from reduced expression of the CCR5 HIV co-receptor, reduced expression of the CXCR4 co receptor, expression of a C-peptide fusion inhibitor (e.g., a C46 fusion inhibitor or a C34 fusion inhibitor) or any combination thereof.
• a C-peptide fusion inhibitor e.g., a C46 fusion inhibitor or a C34 fusion inhibitor
• the cells can also be modified to express any molecule of interest.
• the molecule of interest can be modified as determined by the user or the specific patient need.
• the modified cells are administered with at least one other HIV therapy.
• Suitable other HIV therapies include any HIV therapy known to one of skill in the art.
• Non-limiting examples of other HIV therapies include and combination drugs (e.g., efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atrip la®), emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Complera®), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®), and abacavir/dolutegravir/lamivudine (Triumeq®)), a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) (e.g., abacavir (Ziagen®), efavirenz/emtriacitabine/tenofovir disoproxil fumarate (Atrip la®), la
• tipranavir (Aptivus®), indinavir (Crixivan®), atazanavir/cobicistat (Evotaz®), saquinavir (Invirase®), lopinavir/ritonavir (Kaletra®), fosamprenavir (Lexiva®), ritonavir (Norvir®), darunavir/cobicistat (Prezcobix®), darunavir (Prezista®), atazanavir (Reyataz®), nelfinavir (Viracept®)), an entry inhibitor (e.g., enfuvirtide (Fuzeon®)), an integrase inhibitor (e.g., raltegravir (Isentress®), dolutegravir (Tivicay®), and elvitegravir (Vitekta®)), a chemokine co-receptor antagonists (CCR5 antagonists) (e.g., mar
• the modified cells and the at least one other HIV therapy are administered simultaneously. In other embodiments, the modified cells and the at least one other HIV therapy are administered sequentially. In some embodiments, administration of at least one of the above-mentioned other HIV therapies is expressly excluded, for example, in some embodiments a NRTI is expressly excluded. In some embodiments, no other HIV therapy is administered other than the modified cells disclosed herein and at least one non-myeloablative dose of a chemotherapeutic agent (e.g., busulfan).
• a chemotherapeutic agent e.g., busulfan
• the cells, chemotherapeutic agent, and optionally, other HIV therapies can be administered once to a patient with HIV or can be administered multiple times, e.g., once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 hours, or once every 1, 2, 3, 4, 5, 6 or 7 days, or once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more weeks during therapy, or any ranges between any two of the numbers, end points inclusive.
• methods of treating a patient with HIV comprise mobilizing the patients CD34 + stem cells out of the marrow and into the periphery.
• the cells are mobilized by the administration of G-CSF (Granulocyte-colony stimulating factor).
• G-CSF can be administered as, for example, a 1, 2, 3, 4, or 5 day regimen.
• the G-CSF is administered for 3-5 days.
• the mobilized cells can be captured using methodology, such as apheresis.
• the isolation of the cells, by, for example, apheresis is performed once the CD34 + cell count is or exceeds 10.0 to 20.0 x 10 6 /kg body weight.
• the cell count is or exceeds 5.0 to 25.0 x 10 6 /kg body weight.
• Cd34+ cells are used as the marker to capture the cells for transduction, other cell markers can be used, such as those described herein.
• the cells that are used are isolated based on the presence of a particular marker or combination of markers including, for example, CD34, CD4, Sca-1 CD38, CD123, CD90, CD45, CD133, antigen presenting cell markers (CD8, CD8alpha, CDllb, CDllc, CD103, CD205, CD24, CD115, CD117, CD135, CDllc low , CD45RA, CD123, ILT-7, MHC class II, MHC Class Il iow , TLR7, and/or TRL9).
• the cells are isolated based on the absence of a particular marker, for example, CD3, CD14, CD19, CD56, and/or CD66b. In other embodiments, negative selection is performed for markers of, for example, T cells, B cells, granulocytic, and/or myelomonocytic cells. In some embodiments, cells are isolated based on the presence of Thy- 1 alone or in combination with any other marker. In some embodiments, HSCs are isolated based on LinThyl + Sca-l + expression profile. In some embodiments, mouse HSCs can be isolated by the expression profile CD34 , Scal + , c-kit + . In some embodiments human HSCs can be isolated based on CD34 expression. In some embodiments, the isolated cells are CD34+ or CD4+, or any combination thereof.
• the methods comprise centrifuging the collection of cells. This can be done, for example, to develop a cell rich pellet. The cells can then be re-suspended in a cryopreservation solution and frozen.
• the cryopreservation solution comprises a solution of heparinized Plasmalyte solution and 10% DMSO (Dimethylsulfoxide).
• the cells are initially stored at -4 °C, then the sample will be frozen down to the target temperature of-156°C (when stored in the vapor phase) to -196°C (when stored in the liquid phase).
• the methods comprising infusing the transduced cells into the subject.
• the subject has HIV.
• the subject does not have HIV but is at high risk to obtain HIV and, therefore, desires to become HIV resistant.
• a non-myeloablative dose of the chemotherapeutic such as busulfan is administered.
• chemotherapeutic such as busulfan
• non-myeloablative doses are provided for herein.
• method of treating HIV in a subject comprising administering to the subject a population of cells heterologously expressing ALDH1 and one of: i) a heterologous nucleotide molecule encoding for at least one HIV co-receptor mutant, a mutation or plurality of mutations of at least one HIV co-receptor, at least one HIV fusion inhibitor, a molecule that reduces the expression of a HIV co-receptor, or any combination thereof.
• the methods comprise administering at least one non- myeloablative dose of a chemotherapeutic agent.
• the cells are autologous to the subject. In some embodiments, the cells are allogenic to the subject.
• cells express shCCR5, shCXCR4, and/or a C-peptide fusion inhibitor. Sequences for these proteins can be found, for example, in W02020/018413, which is hereby incorporated by reference in its entirety.
• methods of treating a patient with cancer comprise mobilizing the patients CD34 + stem cells out of the marrow and into the periphery.
• the cells are mobilized by the administration of G- CSF (Granulocyte-colony stimulating factor).
• G-CSF can be administered as, for example, a 1, 2, 3, 4, or 5 day regimen.
• the G-CSF is administered for 3-5 days.
• the mobilized cells can be captured using methodology, such as apheresis.
• the isolation of the cells, by, for example, apheresis is performed once the CD34 + cell count is or exceeds 10.0 to 20.0 x 10 6 /kg body weight.
• the cell count is or exceeds 5.0 to 25.0 x 10 6 /kg body weight.
• Cd34+ cells are used as the marker to capture the cells for transduction, other cell markers can be used, such as those described herein.
• the cells that are used are isolated based on the presence of a particular marker or combination of markers including, for example, CD34, CD4, Sca-1 CD38, CD123, CD90, CD45, CD133, antigen presenting cell markers (CD8, CD8alpha, CDllb, CDllc, CD103, CD205, CD24, CD115, CD117, CD135, CDllc low , CD45RA, CD123, ILT-7, MHC class II, MHC Class II low , TLR7, and/or TRL9).
• the cells are isolated based on the absence of a particular marker, for example, CD3, CD14, CD19, CD56, and/or CD66b.
• negative selection is performed for markers of, for example, T cells, B cells, granulocytic, and/or myelomonocytic cells.
• cells are isolated based on the presence of Thy- 1 alone or in combination with any other marker.
• HSCs are isolated based on Lin hyl + Sca-l + expression profile.
• mouse HSCs can be isolated by the expression profile CD34 , Scal + , c-kit + .
• human HSCs can be isolated based on CD34 expression.
• the isolated cells are CD34+ or CD4+, or any combination thereof.
• the methods comprise centrifuging the collection of cells. This can be done, for example, to develop a cell rich pellet.
• the cells can then be re-suspended in a cryopreservation solution and frozen.
• the cryopreservation solution comprises a solution of heparinized Plasmalyte solution and 10% DMSO (Dimethylsulfoxide).
• the cells are initially stored at -4 °C, then the sample will be frozen down to the target temperature of -156°C (when stored in the vapor phase) to -196°C (when stored in the liquid phase).
• the methods comprise transducing the isolated cells to become resistant to a chemotherapeutic agents, such as busulfan.
• chemotherapeutic resistance can be achieved by the expression of GCLM.
• the GCLM can be introduced to the selected cells through the use of a vector (as described throughout the present specification), such as the use of a lentivral vector.
• the GCLM can be operably connected to a promoter that can be cell specific.
• the promoter is CD34 promoter.
• the promoter is a hCD34 promoter.
• the promoter is a hCD4 promoter.
• the sequence of GCLM is expressed as a protein as provided in SEQ ID NO: 1.
• GCLM is encoded by a nucleic acid molecule comprising the sequence of SEQ ID NO: 2 or the coding region thereof. Due to the degenerate nature of the genetic code the sequence of SEQ ID NO: 2 is provided as a non- limiting example and other nucleic acid molecules can be used to encode for the expression of a protein comprising SEQ ID NO: 1.
• the GCLM comprises 1-10 conservative substitutions that do not change the function of GCLM.
• the expressed GCLM is substantially identical to SEQ ID NO: 1.
• the expression of GCLM in the vector can also be driven by an enhancer element.
• the enhancer element can be a CD3E enhancer.
• CD34 + cells can be isolated by magnetic bead separation.
• Lentiviral vector-mediated human CD34 + cell transduction can include, for example, a 24 h prestimulation of cells in media with the addition of the cytokines Stem Cell Factor (SCF), Fms-related tyrosine kinase 3 ligand (FLT3L), thrombopoietin (TPO), IL-6, IL-2, IL-3, fibronectin, or any combination thereof.
• SCF Stem Cell Factor
• FLT3L Fms-related tyrosine kinase 3 ligand
• TPO thrombopoietin
• IL-6 IL-6
• IL-2 IL-2
• IL-3 fibronectin
• the contacting can be performed in the presence of the cytokines of SCF, FLT3L and TPO (each 100 ng ml -1 ) in serum-free X-Vivo 10 media.
• the cells can then be optionally frozen or not frozen.
• the cell are not contacted with an AAV or AV vector.
• the methods comprising infusing the transduced cells into the subject.
• the subject has cancer.
• a non-myeloablative dose of the chemotherapeutic such as busulfan
• the dosage is a dose of 50-200mg and is given daily.
• the non-myeloablative dose of busulfan is from about 0.15 mg/kg/day to less than 2.5 mg/kg/day, from about 0.4 mg/kg/day to about 1.7 mg/kg/day, or from about 0.8 mg/kg/day to about 1.5 mg/kg/day.
• the non-myeloablative dose of busulfan is about 0.15 mg/kg/day, about 0.2 mg/kg/day, about 0.25 mg/kg/day, about 0.3 mg/kg/day, about 0.35 mg/kg/day, about 0.4 mg/kg/day, about 0.45 mg/kg/day, about 0.5 mg/kg/day, about 0.55 mg/kg/day, about 0.6 mg/kg/day, about 0.65 mg/kg/day, about 0.7 mg/kg/day, about 0.75 mg/kg/day, about 0.8 mg/kg/day, about 0.85 mg/kg/day, about 0.9mg/kg/day, about 0.95 mg/kg/day, about 1.0 mg/kg/day, about 1.1 mg/kg/day, about 1.2 mg/kg/day, about 1.3 mg/kg/day, about 1.4 mg/kg/day, about 1.5 mg/kg/day, about 1.6 mg/kg/day, about 1.7 mg/kg/day, about 1.8 mg/kg/day, about
• the non-myeloablative dose of busulfan is about 1.3 mg/kg/day. In some embodiments, the non-myeloablative dose of busulfan is from about 0.8 mg/kg/day to about 1.6 mg/kg/day, about 0.8 mg/kg/day, about 0.98 mg/kg/day, about 1.3 mg/kg/day, about 1.5 mg/kg/day, or about 1.6 mg/kg/day. In some embodiments, the non-myeloablative dose of busulfan is about 0.5 to about 2 mg/kg/day. The dose can be administered as provided for herein.
• the subject is also treated Fludarabine prior to the infusion of the modified cells.
• the patients are treated with fludarabine (15 mg/m 2 ) for 5 days (until day -1 before the transplant).
• fludarabine 15 mg/m 2
• day -1 before the transplant patients can be treated with 4 mg/kg busulfan.
• the patients are treated day -2 before the transplant with a single dose of 1000mg/m2 busulfan.
• the subject is treated with a non-myeloablative dose of busulfan as provided for herein.
• the subject is treated with a myeloablative of busulfan.
• a single nucleic acid molecule such as a single vector, is used to encode for or express each of the nucleic acid molecules or proteins provided herein.
• a single lentivirus comprises the nucleic acid sequences provided for herein.
• a lentivirus is provided that comprises a single expression construct that encodes for GCLM, or a variant thereof.
• the promoters and response elements that operably connect the nucleic acid molecules that encode for GCLM are non-limiting and other promoters and response elements can be used. One of skill in the art would understand that the different promoters illustrated can be swapped with one another.
• the nucleic acid molecule comprises a 5’ LTR and a 3’ LTR that flanks the nucleic acid molecule encoding for GCLM protein.
• the vector encodes another molecule of interest to be expressed in the same cell as the GCLM protein.
• the nucleic acid molecule comprises a sequence encoding for GCLM and a sequence of interest, which can be for example, any other protein, antisense, miRNA, or other nucleic acid molecule that is desired to be expressed in the bone marrow or the cells types provided for herein.
• chemotherapeutic-resistant modified cells as described above with regard to the disclosed methods, and the use of these cells in the disclosed methods. Also provided are methods of generating these cells by incorporating one or more modifications that confer chemotherapeutic resistance into a suitable cell, and, optionally, incorporating one or more additional modifications unrelated to chemotherapeutic resistance, e.g., additional disease- specific modifications.
• compositions including compositions for use in the methods provided herein, comprising at least one chemotherapeutic-resistant modified cell as provided herein.
• the composition further comprises a pharmaceutically acceptable excipient, diluent, carrier, or any combination thereof.
• the composition may comprise a pharmaceutically acceptable excipient, a pharmaceutically acceptable salt, diluents, carriers, vehicles and such other inactive agents well known to the skilled artisan.
• Vehicles and excipients commonly employed in pharmaceutical preparations include, for example, talc, gum Arabic, lactose, starch, magnesium stearate, cocoa butter, aqueous or non-aqueous solvents, oils, paraffin derivatives, glycols, etc. Solutions can be prepared using water or physiologically compatible organic solvents such as ethanol, 1,2- propylene glycol, polyglycols, dimethylsulfoxide, fatty alcohols, triglycerides, partial esters of glycerine and the like.
• compositions may be prepared using conventional techniques that may include sterile isotonic saline, water, 1,3-butanediol, ethanol, 1,2-propylene glycol, polyglycols mixed with water, Ringer’s solution, etc.
• a coloring agent is added to facilitate in locating and properly placing the composition to the intended treatment site.
• Compositions may include a preservative and/or a stabilizer.
• preservatives include methyl-, ethyl-, propyl- parabens, sodium benzoate, benzoic acid, sorbic acid, potassium sorbate, propionic acid, benzalkonium chloride, benzyl alcohol, thimerosal, phenylmercurate salts, chlorhexidine, phenol, 3-cresol, quaternary ammonium compounds (QACs), chlorbutanol, 2-ethoxyethanol, and imidurea.
• preservatives include methyl-, ethyl-, propyl- parabens, sodium benzoate, benzoic acid, sorbic acid, potassium sorbate, propionic acid, benzalkonium chloride, benzyl alcohol, thimerosal, phenylmercurate salts, chlorhexidine, phenol, 3-cresol, quaternary ammonium compounds (QACs), chlorbutanol
• the composition can comprise a physiological salt, such as a sodium salt.
• a physiological salt such as a sodium salt.
• Sodium chloride (NaCl) is preferred, which may be present at between 1 and 20 mg/ml.
• Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride and calcium chloride.
• Compositions may include one or more buffers.
• Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer; or a citrate buffer.
• Buffers will typically be included at a concentration in the 5-20 mM range.
• the pH of a composition will generally be between 5 and 8, and more typically between 6 and 8 e.g. between 6.5 and 7.5, or between 7.0 and 7.8.
• the composition may include a cryoprotectant agent.
• cryoprotectant agents include a glycol (e.g., ethylene glycol, propylene glycol, and glycerol), dimethyl sulfoxide (DMSO), formamide, sucrose, trehalose, dextrose, and any combinations thereof.
• the cell is part of a population of cultured cells (i.e., in vitro). In another embodiment, the cell is part of a population of cells of a subject (i.e., in vivo).
• the modified cell and/or no n-myelo ablative dose of a chemotherapeutic agent may be delivered to a cell in vivo or a population of cells in vivo that form a tissue or organ in a subject for the purpose of treating or preventing cancer or the disease of interest.
• the modified cells and/or a non-myeloablative dose or myeloablative dose of a chemotherapeutic agent may be delivered to a cultured cell or a population of cultured cells for the purpose of conducting experiments to study its effect on a particular type of cell.
• the composition can be included in an implantable device.
• Suitable implantable devices contemplated by this invention include intravascular stents (e.g., self-expandable stents, balloon- expandable stents, and stent-grafts), scaffolds, grafts, and the like.
• Such implantable devices can be coated on at least one surface, or impregnated, with a composition capable of treating or preventing cancer or other disease.
• compositions can be administered to a subject by any suitable mode and route.
• suitable mode and route include internal, pulmonary, rectal, nasal, vaginal, lingual, intravenous, intraarterial, intramuscular, intraperitoneal, intracutaneous and subcutaneous routes.
• the non-myeloablative or myeloablative dose of the chemotherapeutic can be administered orally, parenterally, intravenously, or as otherwise provided herein.
• cells such as, but not limited to, stem cell or an immune cells are provided that comprise heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• GCL glutamate-cysteine ligase
• the cell comprises heterologous GCLM.
• the cell further comprises at least one additional heterologously expressed molecule of interest.
• the stem cell are fetal stem cells, cord blood derived stem cells, hematopoietic stem cells (HSCs), pluripotent stem cells (PSCs), induced PSCs (iPSCs), embryonic stem cells (ESCs) or cells derived therefrom, such as CD34+ cells, CD90+ cells, CD45+ cells, CD 17+ cells, CD45RA- cells, or any combination thereof.
• the immune cells are T cells.
• the molecule of interest is a chimeric antigen receptor.
• CAR chimeric antigen receptor
• the CAR can be any CAR.
• the cell comprising the heterologous CAR and the heterologous GCLM or related GSH pathway gene product can be used to select for the CAR cells once administered to the patient.
• the heterologous GCLM protein comprises an amino acid sequence of SEQ ID NO: 1 or a variant thereof or a sequence that is at least 90% identical to SEQ ID NO: 1 or is substantially identical to the amino acid sequence of SEQ ID NO: 1.
• the cell does not heterologously express any other proteins that confer chemotherapeutic resistance.
• the cell does not heterologously express ALDH.
• a cell comprises a heterologous nucleotide molecule that encodes for the expression of glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function and one of: i) a heterologous nucleotide molecule encoding for at least one HIV co-receptor mutant, a mutation or plurality of mutations of at least one HIV co-receptor, at least one HIV fusion inhibitor, a molecule that reduces the expression of a HIV co-receptor, or any combination thereof; and/or ii) an endogenous HIV co-receptor mutation or deletion.
• GCL glutamate-cysteine ligase
• the cell comprises a heterologous nucleotide molecule that encodes for GCLM. In some embodiments, the cell comprises a heterologous nucleotide sequence that encodes for a molecule reduces expression of the CCR5; encodes for a reduces expression of the CXCR4; encodes for the expression of a C- peptide fusion inhibitor; or any combination thereof. In some embodiments, the cell expresses shCCR5, shCXCR4, and/or a C-peptide fusion inhibitor, such as C44.
• the cell is modified to express the heterologous nucleotide sequences provided for herein with a non- viral gene transfer system.
• the non- viral gene transfer system is a transposon gene transfer system.
• the transposon gene transfer system is a Sleeping Beauty gene transfer system or a PiggyBac transposon gene transfer system.
• the cell is modified with a CRISPR system to heterologously express GCLM and the other molecules of interest provided for herein.
• GCL glutamate-cysteine ligase
• the heterologous nucleotide sequence encodes a molecule that reduces expression of the CCR5; reduces expression of the CXCR4; encodes for the expression of a C-peptide fusion inhibitor; or any combination thereof.
• the nucleic acid molecule encodes for the expression shCCR5, shCXCR4, and/or a C-peptide fusion inhibitor.
• vectors are provided for as described herein that comprise the nucleic acid molecules provided for herein.
• the vector is a vector that can be used to produce a lentivirus.
• the vector is a lentiviral vector.
• compositions comprising one or more cells as provided for herein.
• the composition is a pharmaceutical compositions.
• Non-limiting examples of pharmaceutical compositions are provided for herein. As described herein, in s
• a pharmaceutical composition comprising the cell of any one of claims VO-
• the cells provided for herein can be used in various methods where chemoprotection can be useful. This can be used, for example, to administer genetically modified chemo-resistant cells to a patient and then use the chemotherapy to kill the non-chemo-resistant cells while the chemo-resistant cells are protected and are allowed to continue to reproduce. This can be used as a way to select for modified cells that express a heterologous protein, such as glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function and a molecule of interest.
• GCL glutamate-cysteine ligase
• GCL glutamate-cysteine ligase
• methods for providing or improving chemoprotection in a target cell comprise providing a target cell with a heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• GCL glutamate-cysteine ligase
• GCLC GCL catalytic subunit
• GCL as a dimer or a full enzyme
• the heterologous protein is GCLM.
• methods for providing or improving chemoprotection in a patient in need thereof are provided.
• the methods comprise administering to the patient a cell expressing a heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• the heterologous protein is GCLM.
• cell further comprises a heterologous molecule of interest, such as a protein or chimeric antigen receptor. Non-limiting examples of such proteins of interest are provided for herein. However, these are non-limiting examples and any molecule of interest could be used in the cell and the methods provided for herein.
• the heterologous expression of glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function allows for post-transplant in vivo selection.
• GCL glutamate-cysteine ligase
• methods of conferring a chemotherapeutic resistant cell to a patient comprise administering a cell expressing heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function to the patient.
• GCL glutamate-cysteine ligase
• the cell heterologously expresses GCLM.
• method of treating a patient with cancer comprises administering to the patient a pharmaceutical composition comprising a cell expressing heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function with a non- myeloablative or a myeloablative dose of a chemotherapeutic.
• GCL glutamate-cysteine ligase
• GCLC GCL catalytic subunit
• GCL as a dimer or a full enzyme
• the cell expresses heterologous GCLM.
• the non-myeloablative or a myeloablative dose of a chemotherapeutic can be administered prior to, after, or simultaneously with the cell expressing heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function, such as GCLM.
• GCL heterologous glutamate-cysteine ligase
• the methods further comprise isolating stem cells or immune cells from the subject.
• the isolated stem cells or immune cells are modified to express heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function, such as GCLM.
• GCL heterologous glutamate-cysteine ligase
• the cells are modified to express heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function by contacting the isolated cells with an expression vector comprising a nucleic acid molecule encoding for glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• GCL heterologous glutamate-cysteine ligase
• the vector is a viral vector a non-viral vector.
• the vector is a lentiviral vector, an adenoviral vector, a plasmid, a retrovirus, a transposon, an episomal expression vector, modified RNA, or any combination thereof.
• the cells can be stem cells or immune cells.
• the stem cell are, but not limited to, fetal stem cells, cord blood derived stem cells, hematopoietic stem cells (HSCs), pluripotent stem cells (PSCs), induced PSCs (iPSCs), embryonic stem cells (ESCs) or cells derived therefrom, such as CD34+ cells, CD90+ cells, CD45+ cells, CD 17+ cells, CD45RA- cells, or any combination thereof.
• the immune cells are T cells.
• the T-cells further comprise a chimeric antigen receptor.
• the modified cells can be autologous to the patient, allogeneic to the patient, or a combination thereof.
• the patient is undergoing gene therapy, cell therapy or CAR- T therapy.
• the chemoprotection provided can be against busulfan and/or naphthalene.
• the methods provided for herein comprise administering to the patient (subject) a myeloablative dose or a non-myeloablative dose of busulfan and/or naphthalene.
• methods of performing a bone marrow transplant in a patient comprise administering to the patient a population of busulfan-resistant modified cells and at least one non-myeloablative or myeloablative dose of busulfan.
• the population of busulfan-resistant modified cells comprises a heterologous gene encoding glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• the heterologous gene encodes GCLM.
• the population of busulfan-resistant modified cells express GCLM.
• the busulfan resistance of busulfan-resistant modified cells is conferred by expression of GCLM.
• greater than 50% of the patient’s bone marrow is replaced with the busulfan-resistant modified cells or cells derived therefrom within 6 months.
• the patient has HIV, cancer, A1AT deficiency, WAS, Hurler Syndrome, Hunter Syndrome, Pompe Disease, Fabry Disease, Mucopolysaccharidoses disorder, MPS 1 H/S (Hurler/Scheie syndrome), MPS I H (Hurler disease), MPS II-(Hunter syndrome), MPS III A, B, C, and D (Sanfillipo syndrome), MPS I S (Scheie syndrome), MPS IV A and B (Morquio syndrome), MPS IX (hyaluronidase deficiency), MPS VII (Sly syndrome), MPS VI (Maroteaux-Lamy syndrome), lysosomal storage diseases, and Childhood cerebral adreno leukodystrophy (cALD).
• MPS 1 H/S H/S
• MPS I H Heurler disease
• MPS III A, B, C, and D Sanfillipo syndrome
• MPS IV A and B Mequi
• the cancer is a hematological cancer or malignancy.
• the hematological cancer is, but not limited to, leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lymphoma, aids- related lymphoma, cutaneous t-cell lymphoma, hodgkin lymphoma, hodgkin lymphoma, mycosis fungoides, non-hodgkin lymphoma, primary central nervous system lymphoma, sezary syndrome, t-cell lymphoma, waldenstrom macroglobulinemia, chronic myeloproliferative neoplasms, langerhans cell histiocytosis, multiple myeloma, myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.
• busulfan resistance provided for herein and throughout can be transient, such that the heterologous expression of a gene product, such as GCLM, is temporary.
• the methods comprise contacting unmodified cells with an expression vector encoding for the expression of glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function to produce the busulfan-resistant modified cells.
• the cell will express GCLM.
• the expression vector is a viral vector or a non- viral vector.
• the viral vector is a lentiviral or adenoviral vector.
• the expression vector is a retrovirus, a transposon, an episomal expression vector, modified RNA, a plasmid, or any combination thereof.
• the at least one non-myeloablative or myeloablative dose of the chemotherapeutic agent is administered after administration of the modified cells.
• the at least one non-myeloablative dose or myeloablative of the chemotherapeutic agent is a non-myeloablative or myeloablative dose of busulfan.
• the non- myeloablative chemotherapeutic agent is administered every day for at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, or at least 6 months.
• the method further comprises not administering the non-myeloablative dose of the chemotherapeutic agent for a period of time between the administering of the busulfan-resistant modified cells and at least one non- myeloablative dose of the chemotherapeutic agent.
• the period of time is selected from the group consisting of about 3 days, about 7 days, about 10 days, and about 14 days.
• the patient is not myeloablated and/or immunocompromised as a result of the administration of the at least one non-myeloablative dose of the chemotherapeutic agent.
• the patient does not experience clinically relevant anemia, neutropenia, thrombocytopenia, pancytopenia, low platelet, low white blood cells, or any combination thereof or related symptoms.
• the modified cells are resistant to HIV infection.
• the modified cells heterologously express a mutation of at least one HIV co-receptor resistant to HIV infection, a mutation or plurality of mutations of at least one HIV co-receptor, at least one HIV fusion inhibitor, a molecule that reduces the expression of a HIV co-receptor, or any combination thereof.
• GCL glutamate-cysteine ligase
• GCLM glutamate-cysteine ligase
• GCLC GCL catalytic subunit
• GCL as a dimer or a full enzyme
• the modified cells heterologously express shCCR5, shCXCR4, a C-peptide fusion inhibitor or any combination thereof. In some embodiments, the modified cells do not express a HIV co-receptor. In some embodiments, the modified cells do not express CCR5, CXCR4, or express CCR5-A32 or a combination thereof.
• methods of treating HIV in a subject comprise administering to the subject a population of cells heterologously expressing glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function and one of: i) a heterologous nucleotide molecule encoding for at least one HIV co-receptor mutant, a mutation or plurality of mutations of at least one HIV co-receptor, at least one HIV fusion inhibitor, a molecule that reduces the expression of a HIV co-receptor, or any combination thereof; and at least one non-myeloablative dose of a chemotherapeutic agent.
• GCL glutamate-cysteine ligase
• the cells heterologously express GCLM. In some embodiments, the cells heterologously express shCCR5, shCXCR4, and/or a C-peptide fusion inhibitor. In some embodiments, the chemotherapeutic agent is busulfan.
• methods of expressing a molecule of interest in a subject comprise administering to the subject a cell that heterologously expresses heterologous glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function and the molecule of interest; and administering a non-myeloablative dose of busuflan.
• the cell heterologously expresses GCLM.
• the cell is CD34+ and/or CD4+, or as otherwise as provided herein, such as the immune cells or stem cells as provided for herein.
• the molecule of interest is one that reduces expression of the CCR5; reduces expression of the CXCR4; encodes for the expression of a C-peptide fusion inhibitor; or any combination thereof.
• the molecule of interest that reduces expression of the CCR5 is shCCR5.
• the molecule of interest is a wild-type protein that is defective in A1AT deficiency, WAS, Hurler Syndrome, Hunter Syndrome, Pompe Disease, Fabry Disease, Mucopolysaccharidoses disorder, MPS 1 H/S (Hurler/Scheie syndrome), MPS I H (Hurler disease), MPS II-(Hunter syndrome), MPS III A, B, C, and D (Sanfillipo syndrome), MPS I S (Scheie syndrome), MPS IV A and B (Morquio syndrome), MPS IX (hyaluronidase deficiency), MPS VII (Sly syndrome), MPS VI (Maroteaux-Lamy syndrome), lysosomal storage diseases, and Childhood cerebral adreno leukodystrophy (cALD).
• the molecule of interest is a chimeric antigen receptor.
• methods of treating cancer in a patient comprise administering busulfan to a patient, wherein the patient has been administered a cell that heterologously expresses glutamate-cysteine ligase (GCL) modifier subunit GCLM, GCLC (GCL catalytic subunit), GCL (as a dimer or a full enzyme), or any other polypeptide in the GSH synthesis pathway that provide the equivalent function.
• GCL glutamate-cysteine ligase
• GCLC GCL catalytic subunit
• GCL as a dimer or a full enzyme
• the cell heterologously expresses GCLM.
• the method comprises administering the cell to the patient prior to administering the busulfan.
• the busulfan is administered in a non-myeloablative dose.
• the busulfan is administered in a myeloablative dose.
• the cancer is a hematological cancer.
• the hematological cancer is leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, lymphoma, aids-related lymphoma, cutaneous t-cell lymphoma, hodgkin lymphoma, hodgkin lymphoma, mycosis fungoides, non-hodgkin lymphoma, primary central nervous system lymphoma, sezary syndrome, T-cell lymphoma, waldenstrom macroglobulinemia, chronic myeloproliferative neoplasms, langerhans cell histiocytosis, multiple myeloma, myelodysplastic syndromes, or myelodysplastic/myeloproliferative
• GCL Glutamate-cysteine ligase
• GSH Glutathione
• Jurkat, CEM, and Tf-la cell lines were transduced with a lentiviral vector that expresses GCLM and green fluorescent protein (GFP) genes.
• Chemoprotection experiments were performed by incubating untransduced or mixed populations of (20% transduced, 80% untransduced) cells with busulfan in concentrations ranging from 0 to 200pg/ml for 1, 2 or 4 hours. Cells were then incubated in busulfan-free culture for 24, 48, 72 and 96h.
• Area under the concentration-time curve (AUC) was estimated by using trapezoidal rule from different times and concentrations of incubation. Pre- and post-exposure GSH levels were measured with fluorometric assays.
• GSH level changes between untransduced and transduced Jurkat, CEM and Tf-la cells were 2.1, 1.7, and 1.9-fold respectively.
• Untransduced CEM cells were found to be most sensitive to busulfan exposure. Cell death and proliferation in all cell cultures were in an AUC- dependent manner.
• the 1.7-fold GSH activity in CEM cells conferred at least 3.5-fold protection against busulfan.
• the purity of transduced CEM cells increased from 20% to 88%, and the viable transduced cell count increased from 30xl0 3 /ml to 84xl0 3 /ml.
• the transduced cells were 100% of the cultures after 72h. Fold expansion in viable transduced cells at 72h was similar to untreated transduced and untransduced controls (2.8, 3.2 and 3.3). GSH levels in transduced cells remained stable throughout the experiment, whereas GSH in untransduced cells was depleted after busulfan exposure. GSH levels in primary human HSPCs were similar to untransduced Tf-la cells. Moreover, RT-PCR analysis showed that GCLM is not highly expressed in these cells.
• HSPCs gene-modified hematopoietic stem/progenitor cells
• results provided herein demonstrate that increasing the GCL enzymatic activity through overexpressing its modifier subunit GCLM was able to confer protection against busulfan toxicity in vitro.
• Jurkat, CEM, and TF-la cell lines were transduced with a lentiviral vector that expresses GCLM and green fluorescent protein (GFP) genes (FIG. 2A).
• Chemoprotection experiments were performed by incubating untransduced or mixed populations of (20% transduced, 80% untransduced) cells with busulfan in concentrations ranging from low (2 to 10 ug/ml) to moderate and high (10 to 200 ug/ml) for 1 or 2 hours.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Medicinal Chemistry (AREA)
• Biomedical Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Wood Science & Technology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biotechnology (AREA)
• Epidemiology (AREA)
• Biochemistry (AREA)
• Virology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Immunology (AREA)
• Microbiology (AREA)
• AIDS & HIV (AREA)
• Emergency Medicine (AREA)
• Communicable Diseases (AREA)
• Tropical Medicine & Parasitology (AREA)
• Physics & Mathematics (AREA)
• Biophysics (AREA)
• Plant Pathology (AREA)
• Cell Biology (AREA)
• Developmental Biology & Embryology (AREA)
• Oncology (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (1)

Family

ID=77079986

Family Applications (1)

Country Status (4)

Citations (4)

Family Cites Families (1)

• 2021
  • 2021-02-01 WO PCT/US2021/016041 patent/WO2021155351A1/en not_active Ceased
  • 2021-02-01 EP EP21747296.8A patent/EP4096649A4/en active Pending
  • 2021-02-01 JP JP2022546650A patent/JP2023512287A/ja active Pending
  • 2021-02-01 CN CN202180020687.3A patent/CN115605084A/zh active Pending

Patent Citations (4)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events